Pharmaceutical Business review

Kaneka’s ubiquinol found effective in heart failure patients

Ubiquinol is the active antioxidant form of Coenzyme Q10 (CoQ10). In the first clinical trial evaluating ubiquinol effects on late-stage congestive heart failure, researchers found that critically ill patients who supplemented with ubiquinol for just three months experienced a 24 to 50% increase in their hearts’s ability to pump blood. In some cases, patients’s plasma levels of CoQ10, which are key to overall heart health, more than tripled.

At the start of the study, each of the patients evaluated had a life expectancy of less than six months. However, all demonstrated significantly improved heart function by the trial’s end, and survived past initial expectations.